Legislators in California are attempting to ban controversial therapies that offer patients the opportunity to change his or her sexual orientation.
On May 8, the California Senate Judiciary Committee approved SB 1172, a patient-protection plan written by Democratic Sen. Ted W. Lieu that would ban children under 18 years of age from sexual orientation change therapies and require adults to sign a consent form that outlines the potential dangers of such treatment and states the therapy has “no medical basis.”
“Some therapists are taking advantage of vulnerable people by pushing dangerous sexual orientation-change efforts,” Lieu said before the committee vote. “These non-scientific efforts have led in some cases to patients later committing suicide, as well as severe mental and physical anguish.”
According to the U.S. Food and Drug Administration, Pfizer Inc. has voluntarily recalled 14 lots of Lo/Ovral-28 and 14 lots of the generic version after the company found some birth control packets had inexact counts of tablets that may be out of sequence.
Typical birth control packets contain 21 pills with active ingredients – in this case, norgestrel and ethinyl estradiol – and seven placebo pills with inert ingredients.
The FDA reports that, “These tablets were manufactured and packaged by Pfizer Inc., commercialized by Akrimax Rx Products and labeled under the Akrimax Pharmaceuticals brand. This product is distributed to warehouses, clinics and retail pharmacies nationwide.”
The U.S. Food and Drug Administration (FDA) recently approved the availability of the emergency contraceptive “morning after pill” for young women under age 16 without a prescription.
Current law allows ladies under age 16 to get the emergency contraceptive pill with a prescription by a physician. Women age 17 and older are allowed to purchase emergency contraceptives, such as Plan B One-Step, over the counter.
This landmark vote was responded to by the U.S. Department of Health and Human Services Secretary Kathleen Sebelius, who used her executive power to override the vote. Margaret Hamburg, a commissioner with the FDA, released the following statement on December 7 regarding the vote reversal.
Domestic Violence Awareness Month helps highlight achievements in reducing domestic violence and the suffering caused by its victims. A recent policy brief shows that suffering is not limited to physical trauma.
According to a UCLA Center for Health Policy Research brief, victims of partner violence not only suffer physical brutalization but also a disproportionately higher level of mental health distress than an unexposed adult.
The brief, released in late August, uses data from the 2009 California Health Interview Survey to show that more than half a million of the 3.5 million Californians who reported being a victim of intimate partner violence (IPV) suffered “serious psychological distress.” This distress includes some of the most serious mental health disorders, such as anxiety and depression. Continue reading Research shows domestic violence victims suffer physical, mental trauma
Not only are women continuing the trend of waiting until later in life to bear children, but the latest U.S. Census shows educated women with college degrees are now more than ever opting to not have children at all.
In a world where couples both likely need to turn a profit to be able to support a family, let alone a mortgage payment or other expenses as they begin to settle down, more women are getting college degrees to get better paying jobs.
According to the U.S. National Institutes of Health, studies of a vaginal gel shows encouraging results in the fight against HIV.
Indevus Pharmaceuticals, Inc., based in Lexington, Mass. has created microbicide PRO 2000, a gel compound that has proved to be safe and 30 percent effective in preventing the AIDS virus from infecting women.
The NIH said that 33 percent effectiveness is considered statistically significant, according to an Associated Press article.
“Although more data are needed to conclusively determine whether PRO 2000 protects women from HIV infection, the results of this study are encouraging,” said National Institute of Allergy and Infectious Diseases (NIAID) director Anthony Fauci in a statement to the AP.